Clinical Trial Update: Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC [Phase 1]

View source ↗

Summary

Phase 1 trial results for AK112, a PD-1/VEGF bispecific antibody, in combination with chemotherapy for extensive-stage small cell lung cancer have been complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• AK112

Snippet

Sponsor: Akeso | Conditions: SCLC, Extensive Stage | Phase 1 | Status: COMPLETED